# Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

> **NCT05061537** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 13 (actual)

## Conditions studied

- Renal Cell Cancer
- Melanoma
- Non-Small-Cell Lung Cancer
- Hepatocellular Cancer
- Bladder Cancer
- Sarcoma
- Head and Neck Cancer
- Colorectal Cancer
- Ovarian Cancer
- Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** PF-07263689
- **BIOLOGICAL:** Sasanlimab

## Key facts

- **NCT ID:** NCT05061537
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-20
- **Primary completion:** 2022-10-14
- **Final completion:** 2022-10-14
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The study was terminated by the Sponsor due to business decision and not due to any safety concerns with PF-07263689. There are no changes to the risk-benefit for participants who have received PF-07263689 in the study.
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061537, "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05061537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*